scholarly journals Dosimetric Factors Used for Thoracic X-Ray Radiotherapy are not Predictive of the Occurrence of Radiation Pneumonitis after Carbon-Ion Radiotherapy

2007 ◽  
Vol 213 (2) ◽  
pp. 149-156 ◽  
Author(s):  
Masashi Koto ◽  
Hirohiko Tsujii ◽  
Naoyoshi Yamamoto ◽  
Hideki Nishimura ◽  
Shogo Yamada ◽  
...  
Keyword(s):  
Radiation Pneumonitis ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
X Ray

scholarly journals Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer

2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Kazuhiko Hayashi ◽  
Naoyoshi Yamamoto ◽  
Masataka Karube ◽  
Mio Nakajima ◽  
Naruhiro Matsufuji ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Pneumonitis ◽  
Locally Advanced ◽  
Carbon Ion Radiotherapy ◽  
Advanced Lung Cancer ◽  
Carbon Ion ◽  
Prognostic Analysis ◽  
Locally Advanced Lung Cancer

scholarly journals Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non–small cell lung cancer

2016 ◽  
Vol 57 (5) ◽  
pp. 548-554 ◽  
Author(s):  
Nobuteru Kubo ◽  
Jun-ichi Saitoh ◽  
Hirofumi Shimada ◽  
Katsuyuki Shirai ◽  
Hidemasa Kawamura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Organs At Risk ◽  
Small Cell ◽  
Carbon Ion Radiotherapy ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Carbon Ion ◽  
X Ray

Abstract The present study compared the dose–volume histograms of patients with Stage IIIA non–small cell lung cancer (NSCLC) treated with carbon ion radiotherapy with those of patients treated with X-ray radiotherapy. Patients with Stage IIIA NSCLC ( n  = 10 patients for each approach) were enrolled. Both radiotherapy plans were calculated with the same targets and organs at risk on the same CT. The treatment plan for the prophylactic lymph node and primary tumor (PTV1) delivered 40 Gy for X-ray radiotherapy and 40 Gy (relative biological effectiveness; RBE) for carbon ion radiotherapy. The total doses for the primary tumor and clinically positive lymph nodes (PTV2) were 60 Gy for X-ray radiotherapy and 60 Gy (RBE) for carbon ion radiotherapy. The homogeneity indexes for PTV1 and PTV2 were superior for carbon ion radiotherapy in comparison with X-ray radiotherapy (PTV1, 0.57 vs 0.65, P  = 0.009; PTV2, 0.07 vs 0.16, P  = 0.005). The normal lung mean dose, V5, V10 and V20 for carbon ion radiotherapy were 7.7 Gy (RBE), 21.4%, 19.7% and 17.0%, respectively, whereas the corresponding doses for X-ray radiotherapy were 11.9 Gy, 34.9%, 26.6% and 20.8%, respectively. Maximum spinal cord dose, esophageal maximum dose and V50, and bone V10, V30 and V50 were lower with carbon ion radiotherapy than with X-ray radiotherapy. The present study indicates that carbon ion radiotherapy provides a more homogeneous target dose and a lower dose to organs at risk than X-ray radiotherapy for Stage IIIA non–small cell lung cancer.

scholarly journals The Risk Factors for Radiation Pneumonitis After Single-Fraction Carbon-Ion Radiotherapy for Lung Cancer or Metastasis

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3229
Author(s):  
Takashi Ono ◽  
Naoyoshi Yamamoto ◽  
Akihiro Nomoto ◽  
Mio Nakajima ◽  
Yuma Iwai ◽  
...  
Keyword(s):  
Risk Factors ◽  
Interstitial Pneumonitis ◽  
Radiation Pneumonitis ◽  
Target Volume ◽  
Carbon Ion Radiotherapy ◽  
Normal Lung ◽  
Carbon Ion ◽  
Single Fraction ◽  
Dose Volume ◽  
Mean Lung Dose

There are no studies on the risk factors of radiation pneumonitis (RP) after carbon-ion radiotherapy at a dose of 50 Gy (relative biological effectiveness (RBE)) in a single fraction. The objective of this study was to identify factors associated with RP after radiotherapy, including dose–volume parameters. Ninety-eight patients without a history of thoracic radiotherapy who underwent treatment for solitary lung tumors between July 2013 and April 2016 were retrospectively analyzed. Treatment was planned using Xio-N. The median follow-up duration was 53 months, and the median clinical target volume was 32.3 mL. Three patients developed grade 2 RP, and one patient developed grade 3 interstitial pneumonitis. None of the patients developed grade 4 or 5 RP. The dose-volume parameters of the normal lung irradiated at least with 5–30 Gy (RBE), and the mean lung dose was significantly lower in patients with grade 0–1 RP than in those with grade 2–3 RP. Pretreatment with higher SP-D and interstitial pneumonitis were significant factors for the occurrence of symptomatic RP. The present study showed a certain standard for single-fraction carbon-ion radiotherapy that does not increase the risk of RP; however, further validation studies are needed.

scholarly journals Carbon-ion radiotherapy for octogenarians with locally advanced non-small-cell lung cancer

2021 ◽  
Author(s):  
Kazuhiko Hayashi ◽  
Naoyoshi Yamamoto ◽  
Mio Nakajima ◽  
Akihiro Nomoto ◽  
Hitoshi Ishikawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Radiation Pneumonitis ◽  
Clinical Stage ◽  
Locally Advanced ◽  
Small Cell ◽  
Carbon Ion Radiotherapy ◽  
Small Cell Lung ◽  
Carbon Ion

Abstract Purpose The clinical significance of carbon-ion radiotherapy (CIRT) for octogenarians with locally advanced non-small-cell lung cancer (LA-NSCLC) remains unclear. We aimed to evaluate the clinical outcomes of CIRT alone for octogenarians with LA-NSCLC. Materials and methods We evaluated 32 patients who underwent CIRT alone between 1997 and 2015. The median age was 82.0 years (range, 80–88 years). In terms of clinical stage (UICC 7th edition), 7 (21.9%), 10 (31.3%), 11 (34.4%), and 4 (12.5%) patients had stage IIA, IIB, IIIA, and ΙΙΙB disease, respectively. The median CIRT dose was 72.0 Gy (relative biological effectiveness), and the median follow-up period was 33.1 months. Results All patients successfully completed CIRT. Regarding grade ≥ 2 toxicities, 1 (3.1%), 3 (9.4%), and 4 (0.7%) patients developed grade 3 radiation pneumonitis, grade 2 radiation pneumonitis, and grade 2 dermatitis, respectively. No grade ≥ 4 toxicities were observed. The 2 year LC, PFS, and OS rates were 83.5%, 46.7%, and 68.0%, respectively. Conclusion CIRT alone is safe and effective for octogenarians with LA-NSCLC.

Carbon-ion Radiotherapy for Esophageal Cancer

2010 ◽  
Vol 61 (2) ◽  
pp. 67-67
Author(s):  
S. Yasuda ◽  
S. Yamada ◽  
H. Imada ◽  
M. Shinoto ◽  
J. Mizoe ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

Unresectable Chondrosarcomas Treated With Carbon Ion Radiotherapy: Relationship Between Dose-averaged Linear Energy Transfer and Local Recurrence

2020 ◽  
Vol 40 (11) ◽  
pp. 6429-6435
Author(s):  
SHINNOSUKE MATSUMOTO ◽  
SUNG HYUN LEE ◽  
REIKO IMAI ◽  
TAKU INANIWA ◽  
NARUHIRO MATSUFUJI ◽  
...  
Keyword(s):  
Energy Transfer ◽  
Local Recurrence ◽  
Linear Energy Transfer ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

scholarly journals Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 339
Author(s):  
Giulia Buizza ◽  
Chiara Paganelli ◽  
Emma D’Ippolito ◽  
Giulia Fontana ◽  
Silvia Molinelli ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Skull Base ◽  
Local Control ◽  
Tumour Progression ◽  
Risk Groups ◽  
Carbon Ion Radiotherapy ◽  
Survival Models ◽  
Carbon Ion ◽  
Combined Models ◽  
Skull Base Chordoma

Skull-base chordoma (SBC) can be treated with carbon ion radiotherapy (CIRT) to improve local control (LC). The study aimed to explore the role of multi-parametric radiomic, dosiomic and clinical features as prognostic factors for LC in SBC patients undergoing CIRT. Before CIRT, 57 patients underwent MR and CT imaging, from which tumour contours and dose maps were obtained. MRI and CT-based radiomic, and dosiomic features were selected and fed to two survival models, singularly or by combining them with clinical factors. Adverse LC was given by in-field recurrence or tumour progression. The dataset was split in development and test sets and the models’ performance evaluated using the concordance index (C-index). Patients were then assigned a low- or high-risk score. Survival curves were estimated, and risk groups compared through log-rank tests (after Bonferroni correction α = 0.0083). The best performing models were built on features describing tumour shape and dosiomic heterogeneity (median/interquartile range validation C-index: 0.80/024 and 0.79/0.26), followed by combined (0.73/0.30 and 0.75/0.27) and CT-based models (0.77/0.24 and 0.64/0.28). Dosiomic and combined models could consistently stratify patients in two significantly different groups. Dosiomic and multi-parametric radiomic features showed to be promising prognostic factors for LC in SBC treated with CIRT.

Sign in / Sign up

Export Citation Format

Share Document